NCT00543582 2015-07-01MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin LymphomaMirati Therapeutics Inc.Phase 2 Terminated23 enrolled
NCT00006019 2013-06-24Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate CancerNational Cancer Institute (NCI)Phase 2 Completed